First-in-human trial of ISIS-FXIRx, an inhibitor of Factor XI production, thought to prevent blood clot formation.
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2011
At a glance
- Drugs IONIS FXIRx (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
- 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2011 Status changed from recruiting to completed, according to an Isis Pharmaceuticals media release.
- 02 Feb 2011 This trial have been initiated according to an Isis Pharmaceuticals media release.